STRUCTURE THERAPEUTICS INC (GPCR) Fundamental Analysis & Valuation

NASDAQ:GPCR • US86366E1064

Current stock price

54.25 USD
-0.26 (-0.48%)
At close:
54.5 USD
+0.25 (+0.46%)
After Hours:

This GPCR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. GPCR Profitability Analysis

1.1 Basic Checks

  • In the past year GPCR has reported negative net income.
  • In the past year GPCR has reported a negative cash flow from operations.
  • In the past 5 years GPCR always reported negative net income.
  • GPCR had a negative operating cash flow in each of the past 5 years.
GPCR Yearly Net Income VS EBIT VS OCF VS FCFGPCR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 -50M -100M -150M -200M

1.2 Ratios

  • GPCR has a Return On Assets of -8.91%. This is in the better half of the industry: GPCR outperforms 69.11% of its industry peers.
  • GPCR's Return On Equity of -9.31% is fine compared to the rest of the industry. GPCR outperforms 75.39% of its industry peers.
Industry RankSector Rank
ROA -8.91%
ROE -9.31%
ROIC N/A
ROA(3y)-13.69%
ROA(5y)-26.89%
ROE(3y)-14.42%
ROE(5y)-29.67%
ROIC(3y)N/A
ROIC(5y)N/A
GPCR Yearly ROA, ROE, ROICGPCR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 -20 -40 -60

1.3 Margins

  • GPCR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GPCR Yearly Profit, Operating, Gross MarginsGPCR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. GPCR Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for GPCR has been increased compared to 1 year ago.
  • Compared to 5 years ago, GPCR has more shares outstanding
  • There is no outstanding debt for GPCR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GPCR Yearly Shares OutstandingGPCR Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 20M 40M 60M
GPCR Yearly Total Debt VS Total AssetsGPCR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • GPCR has an Altman-Z score of 34.54. This indicates that GPCR is financially healthy and has little risk of bankruptcy at the moment.
  • GPCR's Altman-Z score of 34.54 is amongst the best of the industry. GPCR outperforms 92.15% of its industry peers.
  • GPCR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 34.54
ROIC/WACCN/A
WACCN/A
GPCR Yearly LT Debt VS Equity VS FCFGPCR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B

2.3 Liquidity

  • A Current Ratio of 24.81 indicates that GPCR has no problem at all paying its short term obligations.
  • The Current ratio of GPCR (24.81) is better than 95.81% of its industry peers.
  • GPCR has a Quick Ratio of 24.81. This indicates that GPCR is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of GPCR (24.81) is better than 95.81% of its industry peers.
Industry RankSector Rank
Current Ratio 24.81
Quick Ratio 24.81
GPCR Yearly Current Assets VS Current LiabilitesGPCR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. GPCR Growth Analysis

3.1 Past

  • The earnings per share for GPCR have decreased strongly by -75.83% in the last year.
EPS 1Y (TTM)-75.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-76.81%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 20.32% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y58.36%
EPS Next 2Y21.56%
EPS Next 3Y14.44%
EPS Next 5Y20.32%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GPCR Yearly Revenue VS EstimatesGPCR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 2033 1B 2B 3B
GPCR Yearly EPS VS EstimatesGPCR Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 10

More info and screens

Find the best growth stocksShow best growing peers

0

4. GPCR Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for GPCR. In the last year negative earnings were reported.
  • Also next year GPCR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GPCR Price Earnings VS Forward Price EarningsGPCR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GPCR Per share dataGPCR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

  • A more expensive valuation may be justified as GPCR's earnings are expected to grow with 14.44% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.56%
EPS Next 3Y14.44%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. GPCR Dividend Analysis

5.1 Amount

  • GPCR does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

GPCR Fundamentals: All Metrics, Ratios and Statistics

STRUCTURE THERAPEUTICS INC

NASDAQ:GPCR (4/13/2026, 6:25:46 PM)

After market: 54.5 +0.25 (+0.46%)

54.25

-0.26 (-0.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners94.09%
Inst Owner Change-0.01%
Ins Owners3.08%
Ins Owner Change11.39%
Market Cap3.83B
Revenue(TTM)N/A
Net Income(TTM)-141.20M
Analysts85.22
Price Target111.47 (105.47%)
Short Float %23.27%
Short Ratio5.34
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-183.35%
Min EPS beat(2)-209.67%
Max EPS beat(2)-157.04%
EPS beat(4)0
Avg EPS beat(4)-224.39%
Min EPS beat(4)-283.91%
Max EPS beat(4)-157.04%
EPS beat(8)0
Avg EPS beat(8)-201.84%
EPS beat(12)1
Avg EPS beat(12)-167.16%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.19%
PT rev (3m)18.2%
EPS NQ rev (1m)-6.02%
EPS NQ rev (3m)12.46%
EPS NY rev (1m)-0.28%
EPS NY rev (3m)0.66%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.53
P/tB 2.53
EV/EBITDA N/A
EPS(TTM)-4.22
EYN/A
EPS(NY)-1.76
Fwd EYN/A
FCF(TTM)-3.2
FCFYN/A
OCF(TTM)-3.15
OCFYN/A
SpS0
BVpS21.47
TBVpS21.47
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -8.91%
ROE -9.31%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-13.69%
ROA(5y)-26.89%
ROE(3y)-14.42%
ROE(5y)-29.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 271.12%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 24.81
Quick Ratio 24.81
Altman-Z 34.54
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)378.58%
Cap/Depr(5y)573.34%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-75.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-76.81%
EPS Next Y58.36%
EPS Next 2Y21.56%
EPS Next 3Y14.44%
EPS Next 5Y20.32%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-18.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-33.39%
EBIT Next 3Y-15.91%
EBIT Next 5Y25.06%
FCF growth 1Y-91.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-90.51%
OCF growth 3YN/A
OCF growth 5YN/A

STRUCTURE THERAPEUTICS INC / GPCR Fundamental Analysis FAQ

What is the ChartMill fundamental rating of STRUCTURE THERAPEUTICS INC (GPCR) stock?

ChartMill assigns a fundamental rating of 3 / 10 to GPCR.


What is the valuation status of STRUCTURE THERAPEUTICS INC (GPCR) stock?

ChartMill assigns a valuation rating of 0 / 10 to STRUCTURE THERAPEUTICS INC (GPCR). This can be considered as Overvalued.


Can you provide the profitability details for STRUCTURE THERAPEUTICS INC?

STRUCTURE THERAPEUTICS INC (GPCR) has a profitability rating of 1 / 10.